GlassScriptPhysician profile
Rolando Rodriguez
NPI 1245344746
$7,961.56
in general payments reported to CMS, 2019-2025
38 companies · $893 in 2025
The $893 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,663 · 2020: $1,035 · 2021: $1,003 · 2022: $1,195 · 2023: $1,189 · 2024: $983 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,065.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,306.16 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $945.40 | 2019-2025 | |
| Novo Nordisk INC | $896.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $732.28 | 2019-2025 | Synthroid, Ubrelvy |
| Amgen INC. | $516.71 | 2019-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.39 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $422.35 | 2022-2025 | |
| Corcept Therapeutics | $404.42 | 2019-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $255.54 | 2019-2025 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $203.02 | 2019-2024 | Cycloset |
| Radius Health, INC. | $149.82 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $137.32 | 2021-2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $122.90 | 2020-2022 | |
| Dexcom, INC. | $118.24 | 2023-2025 | Dexcom G6 Transmitter |
| Lifescan, INC. | $112.64 | 2020-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $109.95 | 2019 | |
| Merck Sharp & Dohme LLC | $98.40 | 2019-2021 | |
| Mannkind Corporation | $91.17 | 2022-2024 | Afrezza |
| Becton, Dickinson and Company | $84.65 | 2019-2020 | |
| Horizon Therapeutics Plc | $75.48 | 2019-2022 | |
| Pfizer INC. | $74.08 | 2023-2025 | |
| Cvrx, INC. | $74.02 | 2025 | Barostim Neo System |
| Recordati_rare_diseases_inc. | $73.54 | 2021-2025 | Isturisa, Signifor Lar |
| Shire North American Group INC | $63.79 | 2019 | |
| Ibsa Pharma INC. | $62.81 | 2021-2022 | |
| Abbott Laboratories | $56.51 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $53.79 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $45.69 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $29.70 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $26.15 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $22.46 | 2021 | |
| Eusa Pharma (US) LLC | $21.26 | 2022 | |
| Alvogen INC | $19.48 | 2023 | Teriparatide |
| Lundbeck LLC | $19.37 | 2025 | Rexulti |
| Madrigal Pharmaceuticals | $18.26 | 2025 | Rezdiffra |
| Vistapharm, INC. | $16.86 | 2021 | |
| Biomerieux INC | $15.00 | 2025 | Filmarray Gastrointestinal (Gi) Panel |
| Medtronic, INC. | $14.31 | 2024 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rolando Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.